Fresenius SE & Co. (OTCMKTS:FSNUY) Share Price Passes Below Fifty Day Moving Average – Should You Sell?

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $14.78 and traded as low as $14.30. Fresenius SE & Co. shares last traded at $14.36, with a volume of 17,823 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FSNUY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Monday, October 27th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average is $14.78 and its 200-day moving average is $13.32.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.02. The company had revenue of $6.29 billion during the quarter, compared to analyst estimates of $6.38 billion. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.83%. As a group, equities research analysts anticipate that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.